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Background-—Acute exposure to high-altitude hypobaric hypoxia induces a blood pressure rise in hypertensive humans, both at
rest and during exercise. It is unclear whether this phenomenon reﬂects speciﬁc blood pressure hyperreactivity or rather an
upward shift of blood pressure levels. We aimed at evaluating the extent and rate of blood pressure rise during exercise in
hypertensive subjects acutely exposed to high altitude, and how these alterations can be counterbalanced by antihypertensive
treatment.
Methods and Results-—Fifty-ﬁve subjects with mild hypertension, double-blindly randomized to placebo or to a ﬁxed-dose
combination of an angiotensin-receptor blocker (telmisartan 80 mg) and a calcium-channel blocker (nifedipine slow release
30 mg), performed a cardiopulmonary exercise test at sea level and after the ﬁrst night’s stay at 3260 m altitude. High-altitude
exposure caused both an 8 mm Hg upward shift (P<0.01) and a 0.4 mm Hg/mL/kg per minute steepening (P<0.05) of the
systolic blood pressure/oxygen consumption relationship during exercise, independent of treatment. Telmisartan/nifedipine did
not modify blood pressure reactivity to exercise (blood pressure/oxygen consumption slope), but downward shifted (P<0.001) the
relationship between systolic blood pressure and oxygen consumption by 26 mm Hg, both at sea level and at altitude. Muscle
oxygen delivery was not inﬂuenced by altitude exposure but was higher on telmisartan/nifedipine than on placebo (P<0.01).
Conclusions-—In hypertensive subjects exposed to high altitude, we observed a hypoxia-driven upward shift and steepening of the
blood pressure response to exercise. The effect of the combination of telmisartan/nifedipine slow release outweighed these
changes and was associated with better muscle oxygen delivery.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT01830530. ( J Am Heart Assoc. 2018;7:
e008506. DOI: 10.1161/JAHA.117.008506.)
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I n previous articles, we demonstrated that acute exposureto high-altitude hypobaric hypoxia induces a blood pres-
sure (BP) rise in subjects with hypertension, both at rest over
the 24 hours and during exercise,1–3 likely through chemore-
ﬂex-induced sympathetic activation.4–6 Moreover, we also
showed that the combination treatment with telmisartan and
sustained-release formulation of nifedipine gastrointestinal
therapeutic system formulation (GITS) is able to lower BP
levels during exercise not only at sea level but also at high
altitude, as compared with placebo. However, we previously
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reported BP at each workload of exercise2 or immediately
after exercise only,3 without estimating the possible changes
in the rate of BP increase during exercise. Furthermore,
workload is an imprecise surrogate measure for exercise
intensity because there is a considerable variability in the
relationship between workload and oxygen consumption.
Indeed, it is a common experience that a given task (eg,
climbing stairs, which may correspond to a given workload)
may engender extremely different responses in terms of
dyspnea, fatigue, or palpitations when conducted either at sea
level or at high altitude. For these reasons, in a previous
report of ours, we also tried to normalize BP for oxygen
consumption (VO2), the latter being acknowledged as a more
precise indicator of cardiac output and metabolic needs
imposed by exercise than is the measure of workload.
However, we assessed this ratio only at peak exercise and not
dynamically throughout the different exercise steps.2
Thus, it remains debated whether the BP rise during
exercise at high altitude may be the result only of an upward
shift of the BP levels to higher “reference” values or whether
there might be a component of BP hyperreactivity induced by
exercise in hypoxic conditions.7,8 Moreover, it is unclear
whether antihypertensive therapy would just result in a
downward shift of BP levels, or if it might also reduce the rate
of BP increase occurring during exercise, thus modulating BP
hyperreactivity. These questions were not addressed in our
previous article,1–3 and discordant answers were found on the
basis of the results of the few studies that addressed these
issues up to now.7–9
Because of these discrepant or incomplete pieces of
evidence, the clinical signiﬁcance of BP rise during exercise at
altitude in subjects with hypertension has been questioned
recently.9 In an attempt to clarify the above-mentioned open
issues, we have reanalyzed exercise data from the HIGHCARE-
ANDES (High Altitude Cardiovascular Research in the Andes)
Lowlanders Study, obtained both at sea level and at high
altitude.
Methods
Population
One hundred individuals with grade I essential hypertension
(conventional systolic BP 140–159 mm Hg or conventional
diastolic BP 90–99 mm Hg andmean daytime systolic BP ≥135
and <150 mm Hg and/or mean daytime diastolic BP ≥85 and
<95 mm Hg) and no signiﬁcant comorbidities, either untreated
or having previously stopped antihypertensive therapy for
4 weeks, were enrolled in the frame of the HIGHCARE-ANDES
study.1 All subjects were sea-level residents. None of the
subjects had a history of sleep apnea. A full list of inclusion and
exclusion criteria are reported in Data S1.
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
The study protocol was approved by the Ethics Committee
of Istituto Auxologico Italiano (Milan, Italy) and Universidad
Peruana Cayetano Heredia (Lima, Peru), and was conducted in
accordance with the Declaration of Helsinki. All subjects gave
written informed consent to participate.
After enrollment, subjects were randomized to receive a
ﬁxed-dose combination of telmisartan 80 mg/nifedipine-GITS
30 mg or placebo according to a double-blind study design.
Of the study population, 56 randomly chosen individuals
participated in the exercise substudy, in which they repeat-
edly performed a symptom-limited cardiopulmonary exercise
test (CPET) on a cycle-ergometer in different study settings.
Cardiopulmonary Exercise Test
To familiarize patients with the medical personnel and with
the procedure, a CPET was performed whenever possible at
sea level before randomization, ie, in absence of treatment.
The study protocol then focused on CPET performance in 2
conditions:
1. At sea level, after 6 weeks of randomized treatment with
placebo or telmisartan/nifedipine-GITS;
2. At 3260 m above sea level (Huancayo, Peru) 1 week after
the previous CPET.
Clinical Perspective
What Is New?
• We constructed a multipoint blood pressure/oxygen con-
sumption relationship during exercise in hypertensive
individuals randomized either to placebo or to an antihy-
pertensive combination treatment (nifedipine/telmisartan
gastrointestinal therapeutic system formulation), as a way
to normalize blood pressure levels and rate of increase for
metabolic demands and cardiac output changes.
What Are the Clinical Implications?
• High blood pressure during exercise at altitude does not
seem to be a physiological compensation for reduced blood
oxygen content but rather a potentially harmful mechanism
in hypertensive individuals whose hypertension is not
adequately controlled at sea level.
• Hypertensive subjects exposed to high altitude hypobaric
hypoxia display both an upward shift and a steepening of
the blood pressure response to exercise.
• Combination treatment with telmisartan-nifedipine gastroin-
testinal therapeutic system formulation downward shifted
blood pressure levels and improved muscle oxygen delivery
during exercise.
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Details on the CPET methodology are provided in Data S1.
For each subject, systolic BP at each step of exercise was
plotted against VO2 in order to calculate the BP intercept and
the slope of their relationship, as a way to normalize BP
increment for metabolic demand and cardiac output
increase.10 In fact, a constant linear relationship between
cardiac output and VO2 has been demonstrated at sea level as
well as at altitude.11–13 Similarly, the multipoint VO2/work
relationship was constructed, its slope reﬂecting muscle
oxygen delivery (the higher the slope, the better the oxygen
delivery).14
Other Measurements
In the morning before any CPET, we recorded BP at rest (3
measurements) with the patient in a seated position, using a
validated oscillometric device (UA-767 Plus; A&D, Tokyo,
Japan), together with heart rate and blood oxygen saturation
(Masimo Rad-5; Masimo Corporation, Irvine, CA, USA). At high
altitude, patients were questioned for the occurrence of acute
mountain sickness symptoms, using the Lake Louise Score.15
Statistics
Continuous variables are reported as means  standard
deviations. Distribution of the variables in terms of proximity
to normal and the homogeneity of variances were detected by
the Shapiro-Wilk test and Bartlett test, respectively. To assess
the effects of high altitude and treatment on the variables of
interest, we used the linear mixed-effects models with
contrasts a posteriori accounting for repeated measure-
ments,16 ﬁtting the models by maximizing the restricted log-
likelihood. For multiple post hoc comparisons we used the
algorithm that controls the expected rate of false-positive
results for all positive results (false discovery rate).
To evaluate the difference in general characteristics
between the placebo and active groups we used a 2-sample
Wilcoxon signed-rank test for age and a 2-sample t test with
pooled estimates of the sample variance for the other
homoscedastic and normally distributed variables.
An a level of 0.05 was used for all hypothesis tests. All
data analyses were performed using R Core Team (2017,
Vienna, Austria).
Results
One male subject withdrew his consent to be studied before
high-altitude exposure. Thus, data from 55 subjects were
available for analysis (Figure S1). At sea level, before
treatment, the demographic, anthropometric, and BP values
did not differ between the group randomized to combination
treatment or to placebo (Table 1). As shown in Table S1, high-
altitude exposure caused a small BP increase at rest that was
statistically signiﬁcant only for diastolic BP values, with a
concomitant small increase in heart rate and a signiﬁcant
reduction of blood oxygen saturation. Compared to placebo,
telmisartan/nifedipine-GITS signiﬁcantly reduced BP values
both at sea level and at high altitude. At high altitude, patients
developed mild symptoms of acute mountain sickness,
without treatment-related differences (Lake Louise Score
2.02.1 versus 2.01.7, P=0.925, for telmisartan/nifedip-
ine-GITS and placebo, respectively).
Blood Pressure During Exercise
We built a multipoint (≥3 points) systolic BP/VO2 relationship
that was linear, with a coefﬁcient of determination ≥0.70 (on
average, 0.92) in 99% of the tests. The data point from 2
exempliﬁcative cases (1 on active treatment and 1 on
placebo) are plotted in Figure 1.
Estimated marginal means revealed that high-altitude
exposure upward shifted (+8 mm Hg) and steepened
(+0.4 mm Hg/mL/kg per minute) the relationship between
systolic BP and VO2 (Table 2 and Figure 2), independent of
treatment, and that active treatment downward shifted
(26 mm Hg) the relationship between systolic BP and VO2
without affecting its slope.
Cardiorespiratory Variables During Exercise
As shown in Table 3, in patients completing a CPET, high-
altitude exposure signiﬁcantly affected many variables. The
achieved peak respiratory quotient was always >1.00,
indicating achievement of adequately intense exercise levels.
As previously reported, at peak exercise both workload and
Table 1. General Baseline Characteristics of the Study
Population Before Treatment Randomization at Sea Level
T/N-GITS PL P Value
N (men) 27 (13) 28 (16) 
Age, y 508 539 0.235
Weight, kg 7213 7914 0.065
Height, cm 1628 1669 0.113
BMI, kg/m2 27.34.0 28.63.6 0.220
Office SBP, mm Hg 13912 14512 0.088
Office DBP, mm Hg 908 939 0.191
Office HR, bpm 707 738 0.090
Data are expressed as meanstandard deviations. BMI indicates body mass index; DBP,
diastolic blood pressure; HR, heart rate; PL, placebo; SBP, systolic blood pressure; T/N-
GITS, telmisartan 80 mg/nifedipine-GITS 30 mg.
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VO2 were reduced at altitude,
2 as were heart rate and blood
oxygen saturation, without treatment-related differences.
VO2/work slope was not modiﬁed by high-altitude expo-
sure (P=0.482) and always resulted higher on active treat-
ment than on placebo (P=0.006), as shown in Figure 3,
Figure S2, and Table S2.
Discussion
The present study shows that subjects with mild hypertension
acutely exposed to high altitude display an exaggerated,
hypoxia-driven BP response to exercise as a result both of an
upward shift of BP levels at altitude and a steepening of the
BP/VO2 slope. Moreover, our data demonstrate that pharma-
cological treatment (telmisartan/nifedipine-GITS combination)
downward shifted the BP levels both at sea level and at
altitude, albeit not directly contrasting the steepening of BP/
VO2 slope at altitude. Finally, the telmisartan/nifedipine-GITS
combination seemed to improve muscle oxygen delivery
during exercise, both at sea level and at altitude.
Blood Pressure Response During Exercise at High
Altitude
During incremental exercise, cardiac output increases pro-
gressively to match metabolic demand, while systemic
vascular resistance is only slightly reduced, thus resulting in
a BP rise. Aging, presence of hypertension, and environmental
conditions may modify such physiological response to phys-
ical effort, upward shifting, or even steepening the BP–cardiac
output relationship.17–20 This may hold true also for forms of
hypoxia-related BP rise commonly encountered in clinical
practice, such as those observed in case of obstructive sleep
apnea episodes, which can be characterized by nocturnal
hypertension related to hypoxia and sympathetic activation.21
Indeed, we found that exposure to acute hypobaric hypoxia
was responsible for both an upward shift and steepening of
the BP response to exercise in our middle-aged, mildly
hypertensive individuals.
We related systolic BP to VO2 as a way to normalize BP
increase for metabolic demand and cardiac output increase,10
given the need to compare the different conditions in which we
assessed hypertensive individuals in our study. Indeed, it has
been previously shown that the linear relationship between VO2
and cardiac output is maintained at high altitude hypobaric
hypoxia.11–13 This means that at any given level of effort, as
optimally represented by any VO2, systolic BP will be signiﬁ-
cantly higher at 3260 m altitude than at sea level, irrespective
of treatment. Based on our results, a patient with mild
hypertension exercising at high altitude on average will present
with a systolic BP about 10 mm Hg higher than at sea level
during very-low-intensity exercise due to the upward shift of the
BP/VO2 relationship. However, given also the steepening of
such relationship, BP increase will be even more marked when
approaching higher exercise intensities (for instance,
+16 mm Hg as compared to sea level for a VO2 of 20 mL/kg
per minute, ie, a VO2 which is normally achieved at moderate
intensity exercise). In other words, the mean effect of high
altitude on the slope of the systolic BP/VO2 relationship seems
to be small in the case of mild exercise and becomes more
evident when VO2 is higher. This exaggerated BP rise could be a
Figure 1. Multipoint relationship between systolic blood pressure
and oxygen consumption in 2 exempliﬁcative cases randomized to
active treatment (white) and to placebo (black), exercising both at sea
level (circles) and at altitude (triangles). HA indicates high altitude;
SBP, systolic blood pressure; SL, sea level; T/N-GITS, telmisartan
80 mg/nifedipine-GITS 30 mg; VO2, oxygen consumption.
Table 2. Slopes and Intercepts of the Relationship Between Systolic Blood Pressure and Oxygen Consumption During Exercise in
the Different Study Conditions and According to Treatment Group
SL HA
Ptreatment Pvisit Ptreatment9visit
T/N-GITS
(n=25) PL (n=23)
T/N-GITS
(n=23) PL (n=22)
SBP/VO2 intercept 11515 14018 12216 14918 <0.001 0.002 0.670
SBP/VO2 slope 3.21.1 3.91.6 3.71.5 4.21.6 0.091 0.026 0.506
Data are expressed as meanstandard deviations. HA indicates high altitude; PL, placebo; SBP, systolic blood pressure; SL, sea level; T/N-GITS, telmisartan/nifedipine-GITS; VO2, oxygen
consumption.
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consequence of altitude-induced reﬂex activation. We previ-
ously described that during exercise the ventilatory equivalents
for oxygen and CO2 were both higher at altitude compared to
sea level,2 likely as a consequence of augmented peripheral
chemoreﬂex input6,22 and ﬂuid accumulation along the alveolar
capillary membrane.23
Our data, collected after a 1-night stay at altitude are
consistent with real-life hypoxic exposure and diverge from
other data provided in hyperacute hypoxic settings in
laboratory conditions,9 where it was suggested that hypoxia-
induced vasodilation might counteract sympathetic-induced
vasoconstriction with an overall neutral net effect on BP.
Effects of Antihypertensive Therapy
The net effect of active treatment was a downward shift of the
BP/VO2 relationship of about 26 mm Hg. However, it did not
completely counteract hypoxia-driven BP hyperreactivity to
exercise, given that the systolic BP/VO2 slope was higher at
altitude than at sea level independent of treatment. Never-
theless, the magnitude of the BP downward shift induced by
telmisartan/nifedipine-GITS was remarkably greater than the
hypoxia-induced BP rise, especially at low exercise intensities.
Moreover, the VO2/work slope was higher on active
treatment than on placebo, meaning that muscle oxygen
delivery and utilization was more efﬁcient on telmisartan/
nifedipine-GITS, likely as a direct result of BP reduction.24 This
did not translate into improved exercise capacity; however, it
did not result in any adverse effect nor in a reduction of physical
performance. This is at variance from other antihypertensive
drugs suggested to be used at altitude, such as some beta
blockers, thatmay have a negative impact on ventilatory control
and exercise capacity in hypoxic conditions.25–27Moreover, the
slope of the VO2/work relationship was unaffected by high
altitude (3260 m) both in the active treatment group and in the
placebo group, suggesting that during effort, compensatory
mechanisms allow oxygen delivery tomuscles to remain stable.
There are several possible compensatory mechanisms, includ-
ing blood ﬂow redistribution, increased oxygen extraction, and
increased cardiac output for a given work rate.11–13
It should be noted that the VO2/work relationship was a
straight line throughout the entire exercise, which means that
above the anaerobic threshold, when VO2 is cardiac output
dependent, compensatory mechanisms and likely—in this
speciﬁc setting of acute high-altitude exposure—only an
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Figure 2. Systolic blood pressure as a function of oxygen
consumption during exercise in the different study settings and
according to treatment group. In this exempliﬁcative ﬁgure, mean
slopes for each treatment group in each study condition are plotted,
with the relative intercepts. Continuous lines represent the blood
pressure response in a physiological range of VO2 values during
exercise. Dashed lines represent extrapolation until the systolic
blood pressure intercept on the y-axis. HA indicates high altitude;
SBP, systolic blood pressure; SL, sea level; T/N-GITS, telmisartan
80 mg/nifedipine-GITS 30 mg; VO2, oxygen consumption.
Table 3. Cardiopulmonary Variables at Peak Exercise in the 2 Treatment Groups in the Different Study Conditions
SL HA
Ptreatment Ptime Ptreatment9visitT/N-GITS (n=25) PL (n=23) T/N-GITS (n=24) PL (n=22)
Workload, watts 12132 13844 10527 11831 0.261 <0.001 0.271
VO2, mL/kg per min 254 256 233 224 0.737 <0.001 0.912
RQ 1.210.07 1.250.11 1.200.10 1.190.08 0.622 0.006 0.068
VE, L/min 7420 8325 7720 7822 0.386 0.957 0.158
SpO2, % 991 991 895 875 0.364 <0.001 0.145
HR, beats/min 16316 16614 16015 15913 0.711 <0.001 0.065
Data are expressed as meanstandard deviations. HA indicates high altitude; HR, heart rate; RQ, respiratory quotient; SL, sea level; SpO2, peripheral oxyhemoglobin saturation; T/N-GITS,
telmisartan 80 mg/nifedipine-GITS 30 mg; VE, minute ventilation; VO2, oxygen consumption.
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increase in oxygen extraction keep the relationship
unchanged.12,13
Study Limitations
Some limitations of the present study must be acknowledged.
Exercise data were collected in subjects with mild hyperten-
sion after a 1-night stay at 3260 m above sea level. Thus, our
results refer to this speciﬁc cohort and to this speciﬁc time
window during hypoxia exposure, but they may not apply to
subjects with more severe degrees of hypertensive disease, to
exposure to other altitudes, and/or to longer high-altitude
permanence.
Our study population was predominantly composed of
middle-aged Peruvian sea-level residents. Thus, further stud-
ies are needed to show whether our results can be safely
applied to other ethnicities or to wider age ranges.
We did not focus our analysis on diastolic BP because of
the known low accuracy of noninvasive diastolic BP readings
during exercise.28
Perspectives
Subjects with mild hypertension displayed both an upward
shift and a steepening of the BP response to exercise during
acute exposure to high altitude, whose clinical implications, in
particular in subjects characterized by an increased level of
cardiovascular risk, should be better elucidated. The effect of
a combination of a long-acting calcium-channel blocker and a
long-acting angiotensin-receptor blocker outweighed the
hypoxia-induced BP rise during exercise.
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SUPPLEMENTAL MATERIAL 
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Data S1. 
 
Study protocol: complete inclusion and exclusion criteria [1] 
Subjects were included if they fulfilled the following criteria: age 18-65 years; permanent 
residence at low (<500 m) altitude; conventional systolic blood pressure (BP) 140-159 mmHg or 
conventional diastolic BP 90-99 mmHg and mean daytime systolic BP ≥135 and <150 mmHg and/or 
mean daytime diastolic BP ≥85 and <95 mmHg in subjects untreated or after 4 weeks of washout 
from previous treatment; written informed consent to participate in the study. The exclusion 
criteria were: conventional systolic BP ≥150 mmHg and/or conventional diastolic BP ≥95 mmHg in 
treated subjects; regular use of two or more antihypertensive drugs (with the exception of 
subjects on two antihypertensive drugs in low doses); treated antihypertensive subjects in whom 
withdrawal of treatment was deemed unethical; contraindications to angiotensin receptor 
blockers or calcium antagonists; history of serious mountain sickness; subjects who spent 
considerable (> 1 week) amount of time at altitudes above 2500 m during the 3 months preceding 
inclusion in the study; cardiovascular diseases other than hypertension; suspected or confirmed 
secondary hypertension; diabetes mellitus; serious respiratory disorders; other conditions deemed 
relevant by the investigators; BMI ≥35 kg/m2; upper arm circumference >32 cm; known severe 
obstructive sleep apnoea; pregnancy; premenopausal women not using effective contraceptive 
methods; elevated probability of noncompliance with the study procedures. 
 
Cardiopulmonary Exercise Test Methodology 
Cardiopulmonary Exercise Test (CPET) was always performed on a mechanically-braked cycle-
ergometer (Monark Ergomedic 828E, Sweden). Participating individuals either wore a nose clip, 
while breathing through a mouthpiece, or a well-fitting Hans-Rudolph face mask, both connected 
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to the mass flow sensor of the metabolic cart (Vmax SensorMedics 2200, Yorba Linda, CA, USA), 
allowing breath-by-breath collection of ventilation and respiratory gases.  
CPET was preceded by a resting period of 3-5 minutes, and consisted in a 3-minute warm-up 
period (unloaded pedaling), followed by a step-incremental phase during which the work rate was 
increased by 30 W every 3 minutes, in order to allow for a more accurate BP measurement 
corresponding to any given workload. The threshold BP values considered to terminate the test 
were levels >250 mmHg for systolic BP (SBP) and/or >120 mmHg for diastolic BP (DBP)[2]. 
Heart rate (HR), by 12-lead electrocardiogram (Corina Cardiosoft, General Electrics Milwaukee, WI, 
USA) and peripheral oxyhemoglobin saturation (SpO2), by ear-lobe pulse-oxymeter (NPB-295, 
Nellcor Puritan Bennet Inc, Plaseanton, CA, USA), were continuously recorded. Arm BP was 
measured noninvasively always with the same device (auscultatory method) two times at rest, 
during the last minute of each workload step, and at peak exercise always by the same operator 
blinded to the individual’s treatment allocation.  
Individuals were strongly encouraged to perform a maximal test, while allowing them to 
determine when their symptoms were so severe to stop cycling. Objective criteria for interrupting 
exercise were the usual ones defined by guidelines [2]. At HA, oxygen desaturation was considered 
an interruption criterion only if accompanied by symptoms and signs of hypoxemia. 
Tests were always performed in rooms at controlled temperature (19-22 °C). Mean barometric 
pressure recorded during the tests was 750.8±1.0 Torr at SL and 516.0±1.6 Torr at HA.  
Offline analysis of CPET data was performed in accordance with recommendations [2,3] by two 
independent observers blinded to study treatment. In case of non-agreement between them, a 
third independent reader analyzed the test. The average values of the cardiorespiratory variables 
obtained during the last minute of each step of exercise were considered representative of its 
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corresponding workload. Peak exercise was defined as the exercise performed during the last 30 
seconds of the test. 
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Table S1. Parameters recorded in resting conditions at SL and at HA in the two treatment groups. 
 SL HA 
 
T/N-GITS 
 (n=27) 
PL  
(n=28) 
T/N-GITS  
(n=27) 
PL  
(n=28) 
p treatment p visit p treatment x visit 
Office SBP  123±16 142±14 124±12 148±11 <0.001 0.122 0.396 
Office DBP 78±11 92±10 82±9 95±10 <0.001 0.033 0.882 
Office HR 75±9 75±10 82±13 77±8 0.200 0.049 0.170 
SpO2 98±2 98±2 90±3 90±4 0.832 <0.001 0.486 
 
SL=sea level; HA=high altitude; T/N-GITS= telmisartan 80 mg/nifedipine-GITS 30 mg; PL=placebo; 
SBP=systolic blood pressure (mmHg); DBP=diastolic blood pressure (mmHg); HR=heart rate (bpm); 
SpO2=peripheral oxyhemoglobin saturation. 
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Table S2. Slopes and intercepts of the relationship between oxygen consumption and workload 
during exercise in the different study conditions and according to treatment group.  
 
 SL HA 
 
T/N-GITS 
 (n=25) 
PL  
(n=23) 
T/N-GITS  
(n=23) 
PL  
(n=22) 
p treatment p visit p treatment x visit 
VO2/work intercept 
(mL/Kg/min) 
4.7±0.9 4.3±0.4 4.8±1.0 4.8±1.4 0.305 0.062 0.234 
VO2/work slope 
(mL/Kg/min/watt) 
182±32 163±32 184±36 156±32 0.006 0.482 0.149 
 
PL=placebo; T/N-GITS=telmisartan/nifedipine-GITS; VO2=oxygen consumption. 
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Figure S1. CONSORT flow diagram.  
 
Reasons for cardiopulmonary exercise test interruption (exhaustion, blood pressure or signs/symptoms of 
myocardial ischemia) are shown for the different study conditions and according to the treatment groups. 
CPET=cardiopulmonary exercise test; M=males; F=females; T/N-GITS= telmisartan 80 mg + nifedipine 
Gastro-Intestinal Therapeutic System 30 mg; SL=sea level; HA=high altitude; BP=blood pressure. 
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Figure S2. Relationship between oxygen consumption and workload in the two treatment groups in the 
different study conditions.  
 
 
 
Continuous lines represent the mean slope value for each treatment group both at sea level (in blue) and at 
altitude (in red) in a physiological range of workload. Dashed lines represent extrapolation until the oxygen 
consumption intercept on the y-axis. HA=high altitude; SL =sea level; T/N-GITS=telmisartan 80 
mg/nifedipine-GITS 30 mg; VO2=oxygen consumption 
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